Cargando…
First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: a validation study
BACKGROUND: The nadir value of the absolute neutrophil count (ANC) in the first cycle of chemotherapy is an effective predictor of subsequent neutropenic events. This study was designed to validate an earlier published study based on a retrospective data analysis from a prospective randomized clinic...
Autores principales: | Rivera, Edgardo, Haim Erder, M, Fridman, Moshe, Frye, Debra, Hortobagyi, Gabriel N |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC314422/ https://www.ncbi.nlm.nih.gov/pubmed/12927041 |
Ejemplares similares
-
Interpreting the Results of a Retrospective Comparison of Test and Reference Treatments in a Randomized Clinical Trial Setting
por: Fridman, Moshe, et al.
Publicado: (2014) -
Days of Prophylactic Filgrastim Use to Reduce Febrile Neutropenia in Patients
por: Scott, Shane J., et al.
Publicado: (2003) -
64. Absolute Monocyte Count (AMC) as Early and Safe Marker for Discharge in Low-risk Pediatric Febrile Neutropenia with Cancer
por: Alali, Muayad, et al.
Publicado: (2021) -
Pretreatment monocyte counts and neutrophil counts predict the risk for febrile neutropenia in patients undergoing TPF chemotherapy for head and neck squamous cell carcinoma
por: Shimanuki, Marie, et al.
Publicado: (2018) -
Prescribing Empiric Antibiotics for Febrile Neutropenia: Compliance with Institutional Febrile Neutropenia Guidelines
por: Naeem, Doaa, et al.
Publicado: (2018)